Recent work by Peshin et al. on immunotherapy in gastrointestinal malignancies underscores the clinical utility of PD-1/PD-L1 checkpoint inhibitors in MSI-H and PD-L1-positive tumors, reinforcing their potential relevance in biomarker-selected pancreatic cancer populations [74]. The gene discussed is CD274; the disease is pancreatic neoplasm.